Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Update

Gyre Therapeutics, Inc. (NASDAQ:GYRE) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 832,200 shares, a growth of 51.5% from the November 30th total of 549,400 shares. Based on an average daily volume of 78,700 shares, the days-to-cover ratio is presently 10.6 days. Currently, 3.8% of the company’s shares are short sold.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of GYRE. Charles Schwab Investment Management Inc. increased its stake in Gyre Therapeutics by 392.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after buying an additional 90,557 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Gyre Therapeutics by 16.9% in the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after acquiring an additional 43,840 shares in the last quarter. Advantage Alpha Capital Partners LP purchased a new stake in shares of Gyre Therapeutics during the third quarter valued at approximately $334,000. WINTON GROUP Ltd bought a new stake in Gyre Therapeutics during the second quarter worth $220,000. Finally, Bank of New York Mellon Corp bought a new stake in Gyre Therapeutics during the second quarter worth $218,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Price Performance

Shares of NASDAQ GYRE traded down $0.68 during trading on Friday, hitting $12.45. 155,388 shares of the company traded hands, compared to its average volume of 75,608. The business’s fifty day moving average is $12.71 and its 200 day moving average is $12.63. Gyre Therapeutics has a fifty-two week low of $8.26 and a fifty-two week high of $27.45.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.